101 Montgomery Street
About Audentes TherapeuticsAudentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.
134 articles with Audentes Therapeutics
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.
Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies
Audentes Therapeutics, an Astellas Company, today announced that it is expanding its mission to develop potentially life-changing genetic medicines by becoming Astellas Gene Therapies.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
The agency placed the hold on the Astellas company’s trial after two patients died in the trial.
Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)
Audentes Therapeutics , an Astellas genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). XLMTM is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death. “We are grateful for t
Clinical Catch-Up: August 17-21
8/24/2020It was a relatively quiet week for clinical trial news. Here’s a look.
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy
Audentes Therapeutics, Inc., an Astellas company, announced that a third study patient has passed away in the ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy, which is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Clinical Catch-Up: June 29-July 3
7/6/2020Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
Audentes Therapeutics Appoints Julie Person as Senior Vice President, Human Resources
Audentes Therapeutics, Inc., an Astellas genetic medicines company, announced that it has appointed Julie Person as Senior Vice President, Human Resources.
It is planned to go into operation in 2021, and is expected to create more than 200 new jobs in Lee County, North Carolina.
Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina
Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot, state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina
Astellas Completes Acquisition of Audentes Therapeutics
Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
Astellas Pharma Inc. and Audentes Therapeutics, Inc., announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion..
Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND on track for first quarter 2020 submission